Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2016

01-10-2016 | Review

Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients

Authors: Ulla Feldt-Rasmussen, Marianne Klose

Published in: Endocrine | Issue 1/2016

Login to get access

Abstract

Hypothyroidism is characterized by hypometabolism, and may be seen as a part of secondary failure due to pituitary insufficiency or tertiary due to hypothalamic disease. Secondary and tertiary failures are also referred to as central hypothyroidism. Whereas overt primary hypothyroidism has a well-known affection on the heart and cardiovascular system, and may result in cardiac failure, cardiovascular affection is less well recognized in central hypothyroidism. Studies on central hypothyroidism and cardiovascular outcome are few and given the rarity of the diseases often small. Further, there are several limitations given vast difficulties in diagnosing the condition correctly biochemically, and difficulties monitoring the treatment because normal thyroid–pituitary feedback interrelationships are disrupted. The present review summarizes available studies of central adult hypothyroidism and its possible influence on the cardiovascular system, describe differences from primary thyroid failure and seek evidence for performing guidelines for clinical management of this particular thyroid and hypothalamo-pituitary disorder.
Literature
1.
L. Persani, Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J. Clin. Endocrinol. Metab. 97, 3068–3078 (2012)CrossRefPubMed
2.
M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, E.J. Grimley, D.M. Hasan, H. Rodgers, F. Tunbridge, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. 43, 55–68 (1995)CrossRef
3.
K. Hashimoto, The etiology of isolated thyroid stimulating hormone deficiency. Intern. Med. 37, 231–232 (1998)CrossRefPubMed
4.
U. Feldt-Rasmussen, Treatment of hypothyroidism in elderly patients and in patients with cardiac disease. Thyroid 17, 619–624 (2007)CrossRefPubMed
5.
I. Klein, K. Ojamaa, Clinical review 36: cardiovascular manifestations of endocrine disease. J. Clin. Endocrinol. Metab. 75, 339–342 (1992)PubMed
6.
D.H. Streeten, G.H. Anderson Jr., T. Howland, R. Chiang, H. Smulyan, Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 11, 78–83 (1988)CrossRefPubMed
7.
T. Friis, L.R. Pedersen, Serum lipids in hyper- and hypothyroidism before and after treatment. Clin. Chim. Acta 162, 155–163 (1987)CrossRefPubMed
8.
J. Dernellis, M. Panaretou, Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am. Heart J. 143, 718–724 (2002)CrossRefPubMed
9.
K. Obuobie, J. Smith, L.M. Evans, R. John, J.S. Davies, J.H. Lazarus, Increased central arterial stiffness in hypothyroidism. J. Clin. Endocrinol. Metab. 87, 4662–4666 (2002)CrossRefPubMed
10.
P. Clausen, H. Mersebach, B. Nielsen, B. Feldt-Rasmussen, U. Feldt-Rasmussen, Hypothyroidism is associated with signs of endothelial dysfunction despite 1-year replacement therapy with levothyroxine. Clin. Endocrinol. 70, 932–937 (2009)CrossRef
11.
B. Biondi, Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur. J. Endocrinol. 167, 609–618 (2012)CrossRefPubMed
12.
L.H. Salomo, A.H. Laursen , N. Reiter, U. Feldt-Rasmussen: Myxoedema coma: an almost forgotten, yet still existing cause of multiorgPlease provide the volume number and page range in reference number 12.an failure. BMJ Case Rep. 2014 (2014)
13.
B. Biondi, E.A. Palmieri, G. Lombardi, S. Fazio, Subclinical hypothyroidism and cardiac function. Thyroid 12, 505–510 (2002)CrossRefPubMed
14.
M. Klose, D. Marina, M.L. Hartoft-Nielsen, O. Klefter, V. Gavan, L. Hilsted, A.K. Rasmussen, U. Feldt-Rasmussen, Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J. Clin. Endocrinol. Metab. 98, 3802–3810 (2013)CrossRefPubMed
15.
N.H. Filipsson, U. Feldt-Rasmussen, I. Kourides, V. Popovic, M. Koltowska-Haggstrom, B. Jonsson, G. Johannsson, The metabolic consequences of thyroxine replacement in adult hypopituitary patients. Pituitary 15, 495–504 (2012)CrossRef
16.
M. Yamada, M. Mori, Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat. Clin. Pract. Endocrinol. Metab. 4, 683–694 (2008)CrossRefPubMed
17.
D. Preiss, L. Todd, M. Panarelli, Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results. Ann. Clin. Biochem. 45, 70–75 (2008)CrossRefPubMed
18.
P. Beck-Peccoz, L. Persani, Variable biological activity of thyroid-stimulating hormone. Eur. J. Endocrinol. 131, 331–340 (1994)CrossRefPubMed
19.
L. Persani, E. Ferretti, S. Borgato, G. Faglia, P. Beck-Peccoz, Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J. Clin. Endocrinol. Metab. 85, 3631–3635 (2000)PubMed
20.
R. Abs, U. Feldt-Rasmussen, A.F. Mattsson, J.P. Monson, B.A. Bengtsson, M.I. Goth, P. Wilton, M. Koltowska-Haggstrom, Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur. J. Endocrinol. 155, 79–90 (2006)CrossRefPubMed
21.
A.F. Attanasio, P.C. Bates, K.K. Ho, S.M. Webb, R.J. Ross, C.J. Strasburger, R. Bouillon, B. Crowe, K. Selander, D. Valle, S.W. Lamberts, Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status—3-year results from the HypoCCS Database. J. Clin. Endocrinol. Metab. 87, 1600–1606 (2002)PubMed
22.
C. Hoybye, L. Savendahl, H.T. Christesen, P. Lee, B.T. Pedersen, M. Schlumpf, J. Germak, J. Ross, The NordiNet(R) International Outcome Study and NovoNet(R) ANSWER Program(R): rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin(R)). J. Clin. Epidemiol. 5, 119–127 (2013)CrossRef
23.
S. Grunenwald, P. Caron, Central hypothyroidism in adults: better understanding for better care. Pituitary 18, 169–175 (2015)CrossRefPubMed
24.
U. Feldt-Rasmussen, Interactions between growth hormone and the thyroid gland—with special reference to biochemical diagnosis. Curr. Med. Chem. 14, 2783–2788 (2007)CrossRefPubMed
25.
J.A. Romijn, J.W. Smit, S.W. Lamberts, Intrinsic imperfections of endocrine replacement therapy. Eur. J. Endocrinol. 149, 91–97 (2003)CrossRefPubMed
26.
L.S. Constine, P.D. Woolf, D. Cann, G. Mick, K. McCormick, R.F. Raubertas, P. Rubin, Hypothalamic-pituitary dysfunction after radiation for brain tumors. N. Engl. J. Med. 328, 87–94 (1993)CrossRefPubMed
27.
P.J. Snyder, B.F. Fowble, N.J. Schatz, P.J. Savino, T.A. Gennarelli, Hypopituitarism following radiation therapy of pituitary adenomas. Am. J. Med. 81, 457–462 (1986)CrossRefPubMed
28.
B.M. Arafah, Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 62, 1173–1179 (1986)CrossRefPubMed
29.
30.
31.
S.I. Sherman, J. Gopal, B.R. Haugen, A.C. Chiu, K. Whaley, P. Nowlakha, M. Duvic, Central hypothyroidism associated with retinoid X receptor-selective ligands. N. Engl. J. Med. 340, 1075–1079 (1999)CrossRefPubMed
32.
O. Abdel-Rahman, H. ElHalawani, M. Fouad, Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol. 12, 413–425 (2016)CrossRefPubMed
33.
F. Torino, A. Barnabei, R.M. Paragliola, P. Marchetti, R. Salvatori, S.M. Corsello, Endocrine side-effects of anticancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur. J. Endocrinol. 169, R153–R164 (2013)CrossRefPubMed
34.
M.C. Zatelli, E. Gentilin, F. Daffara, F. Tagliati, G. Reimondo, G. Carandina, M.R. Ambrosio, M. Terzolo, E.C. Degli Uberti, Therapeutic concentrations of mitotane (o,p’-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151, 2453–2461 (2010)CrossRefPubMed
35.
M. Russo, C. Scollo, G. Pellegriti , O.R. Cotta, S. Squatrito, F. Frasca, S. Cannavo, D. Gullo : Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clin. Endocrinol. (2015)
36.
G.J. Beckett, A.D. Toft, First-line thyroid function tests—TSH alone is not enough. Clin. Endocrinol.. 58, 20–21 (2003)CrossRef
37.
38.
A.P. Weetman, Hypothyroidism: screening and subclinical disease. Br. Med. J. 314, 1175–1178 (1997)CrossRef
39.
40.
Z. Baloch, P. Carayon, B. Conte-Devolx, L.M. Demers, U. Feldt-Rasmussen, J.F. Henry, V.A. LiVosli, P. Niccoli-Sire, R. John, J. Ruf, P.P. Smyth, C.A. Spencer, J.R. Stockigt, Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13, 3–126 (2003)CrossRefPubMed
41.
U. Feldt-Rasmussen, P.P. Hyltoft, O. Blaabjerg, M. Horder, Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. Acta Endocrinol. 95, 328–334 (1980)PubMed
42.
S. Andersen, K.M. Pedersen, N.H. Bruun, P. Laurberg, Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J. Clin. Endocrinol. Metab. 87, 1068–1072 (2002)CrossRefPubMed
43.
V. Panicker, S.G. Wilson, T.D. Spector, S.J. Brown, M. Falchi, J.B. Richards, G.L. Surdulescu, E.M. Lim, S.J. Fletcher, J.P. Walsh, Heritability of serum TSH, free T4 and free T3 concentrations: a study of a large UK twin cohort. Clin. Endocrinol. 68, 652–659 (2008)CrossRef
44.
M.L. Hartoft-Nielsen, M. Lange, A.K. Rasmussen, S. Scherer, T. Zimmermann-Belsing, U. Feldt-Rasmussen, Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Horm. Res. 61, 53–57 (2004)CrossRefPubMed
45.
O. Koulouri, M.A. Auldin, R. Agarwal, V. Kieffer, C. Robertson, S.J. Falconer, M.J. Levy, T.A. Howlett, Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin. Endocrinol. 74, 744–749 (2011)CrossRef
46.
G. Carosi, E. Malchiodi, E. Ferrante, E. Sala, E. Verrua, E. Profka, C. Giavoli, M. Filopanti, P. Beck-Peccoz, A. Spada, G. Mantovani, Hypothalamic-pituitary axis in non-functioning pituitary adenomas: focus on the prevalence of isolated central hypoadrenalism. Neuroendocrinology 102, 267–273 (2015)CrossRefPubMed
47.
I. Vanhorebeek, G. Van den Berghe, The neuroendocrine response to critical illness is a dynamic process. Crit. Care Clin. 22, 1–15 (2006). vCrossRefPubMed
48.
Y. Oto, K. Muroya, J. Hanakawa, Y. Asakura, M. Adachi, The ratio of serum free triiodothyronine to free thyroxine in children: a retrospective database survey of healthy short individuals and patients with severe thyroid hypoplasia or central hypothyroidism. Thyroid Res. 8, 10 (2015)CrossRefPubMedPubMedCentral
49.
Y. Hirata, H. Fukuoka, G. Iguchi, Y. Iwahashi, Y. Fujita, Y. Hari, M. Iga, S. Nakajima, Y. Nishimoto, M. Mukai, Y. Hirota, K. Sakaguchi, W. Ogawa, Y. Takahashi, Median-lower normal levels of serum thyroxine are associated with low triiodothyronine levels and body temperature in patients with central hypothyroidism. Eur. J. Endocrinol. 173, 247–256 (2015)CrossRefPubMed
50.
L. Persani, M. Bonomi, Uncertainties in endocrine substitution therapy for central endocrine insufficiencies: hypothyroidism. Handb. Clin. Neurol. 124, 397–405 (2014)CrossRefPubMed
51.
J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn, Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358, 861–865 (2001)CrossRefPubMed
52.
T.H. Collet, J. Gussekloo, D.C. Bauer, W.P. den Elzen, A.R. Cappola, P. Balmer, G. Iervasi, B.O. Asvold, J.A. Sgarbi, H. Volzke, B. Gencer, R.M. Maciel, S. Molinaro, A. Bremner, R.N. Luben, P. Maisonneuve, J. Cornuz, A.B. Newman, K.T. Khaw, R.G. Westendorp, J.A. Franklyn, E. Vittinghoff, J.P. Walsh, N. Rodondi, Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 172, 799–809 (2012)CrossRefPubMed
53.
I. Shimon, O. Cohen, A. Lubetsky, D. Olchovsky, Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 12, 823–827 (2002)CrossRefPubMed
54.
J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24, 1670–1751 (2014)CrossRefPubMedPubMedCentral
55.
I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344, 501–509 (2001)CrossRefPubMed
56.
J.V. Hennessey, J.R. Garber, K.A. Woeber, R. Cobin, I. Klein, American association of clinical endocrinologists and American college of endocrinology position statement on thyroid dysfunction case finding. Endocr. Pract. 22, 262–270 (2016)CrossRefPubMed
57.
B. Harbeck, C.S. Haas, S. Suefke, H. Moenig, Cardiovascular risk factors and disease in patients with hypothalamic-pituitary disorders. Int. J. Cardiol. 184, 464–465 (2015)CrossRefPubMed
58.
B. Bulow, L. Hagmar, Z. Mikoczy, C.H. Nordstrom, E.M. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 46, 75–81 (1997)CrossRef
59.
J. Lindholm, E.H. Nielsen, P. Bjerre, J.S. Christiansen, C. Hagen, S. Juul, J. Jorgensen, A. Kruse, P. Laurberg, K. Stochholm, Hypopituitarism and mortality in pituitary adenoma. Clin. Endocrinol. 65, 51–58 (2006)CrossRef
60.
E.M. Erfurth, P. Siesjo, T. Bjork-Eriksson, Pituitary disease mortality: is it fiction? Pituitary 16, 402–412 (2013)CrossRefPubMed
61.
R.N. Clayton, Mortality, cardiovascular events and risk factors in hypopituitarism. Growth Horm. IGF Res. 8(Suppl A), 69–76 (1998)CrossRefPubMed
62.
T. Rosen, B.A. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285–288 (1990)CrossRefPubMed
63.
J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 (2001)CrossRefPubMed
64.
A. Colao, O.R. Cotta, D. Ferone, M.L. Torre, F. Ferrau, S.C. Di, M. Boschetti, C. Teti, M.C. Savanelli, A. Alibrandi, F. Trimarchi, S. Cannavo, Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. Clin. Endocrinol. 79, 211–216 (2013)CrossRef
65.
J.C. Smith, Hormone replacement therapy in hypopituitarism. Expert Opin. Pharmacother. 5, 1023–1031 (2004)CrossRefPubMed
66.
R. Abs, A.F. Mattsson, B.A. Bengtsson, U. Feldt-Rasmussen, M.I. Goth, M. Koltowska-Haggstrom, J.P. Monson, J. Verhelst, P. Wilton, Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm. IGF Res. 15, 349–359 (2005)CrossRefPubMed
67.
M. Klose, B. Jonsson, R. Abs, V. Popovic, M. Koltowska-Haggstrom, B. Saller, U. Feldt-Rasmussen, I. Kourides, From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum—a KIMS analysis. Eur. J. Endocrinol. 161(Suppl 1), S75–S83 (2009)CrossRefPubMed
68.
K. Danilowicz, O.D. Bruno, M. Manavela, R.M. Gomez, A. Barkan, Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 11, 279–285 (2008)CrossRefPubMed
69.
G. Johannsson, O. Ragnarsson, Cardiovascular and metabolic impact of glucocorticoid replacement therapy. Front Horm. Res. 43, 33–44 (2014)PubMed
70.
C. Ukita, H. Miyazaki, N. Toyoda, A. Kosaki, M. Nishikawa, T. Iwasaka, Takotsubo cardiomyopathy during acute adrenal crisis due to isolated adrenocorticotropin deficiency. Intern. Med. 48, 347–352 (2009)CrossRefPubMed
71.
G.F. Pecori, L.M. Fatti, F. Cavagnini, Isolated corticotrophin deficiency presenting with pericardial effusion. J. Endocrinol. Invest. 28, 831–833 (2005)CrossRef
72.
K. Kanamori, R. Yamashita, K. Tsutsui, M. Hara, Y. Murakawa, Long QT syndrome associated with adrenal insufficiency in a patient with isolated adrenocorticotropic hormone deficiency. Intern. Med. 53, 2329–2331 (2014)CrossRefPubMed
73.
A.N. Shah, S.W. Dubrey, D. Thomas, Hypothyroid cardiomyopathy due to hypopituitarism: a diagnostic dilemma. Clin. Med. 7, 639–640 (2007)CrossRef
74.
W. Huang, J. Xu, F. Jing, W.B. Chen, L. Gao, H.T. Yuan, J.J. Zhao, Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion. Endocrine 46, 328–339 (2014)CrossRefPubMed
75.
F. Wang, Y. Tan, C. Wang, X. Zhang, Y. Zhao, X. Song, B. Zhang, Q. Guan, J. Xu, J. Zhang, D. Zhang, H. Lin, C. Yu, J. Zhao, Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J. Clin. Endocrinol. Metab. 97, 2724–2731 (2012)CrossRefPubMed
76.
C. Xu, X. Yang, W. Liu, H. Yuan, C. Yu, L. Gao, J. Zhao, Thyroid stimulating hormone, independent of thyroid hormone, can elevate the serum total cholesterol level in patients with coronary heart disease: a cross-sectional design. Nutr. Metab. 9, 44 (2012)CrossRef
77.
O.M. Dekkers, A.M. Pereira, F. Roelfsema, J.H. Voormolen, K.J. Neelis, M.A. Schroijen, J.W. Smit, J.A. Romijn, Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J. Clin. Endocrinol. Metab. 91, 1796–1801 (2006)CrossRefPubMed
78.
M. Wichers-Rother, S. Hoven, R.A. Kristof, N. Bliesener, B. Stoffel-Wagner, Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery. Exp. Clin. Endocrinol. Diabetes 112, 323–327 (2004)CrossRefPubMed
79.
C. Alameda, T. Lucas, E. Pineda, M. Brito, J.G. Uria, R. Magallon, J. Estrada, B. Barcelo, Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy. J. Endocrinol. Invest. 28, 18–22 (2005)CrossRefPubMed
80.
Y. Greenman, G. Ouaknine, I. Veshchev, I.I. Reider-Groswasser, Y. Segev, N. Stern, Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin. Endocrinol. 58, 763–769 (2003)CrossRef
81.
M. Marazuela, B. Astigarraga, A. Vicente, J. Estrada, C. Cuerda, J. Garcia-Uria, T. Lucas, Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas. J. Endocrinol. Invest. 17, 703–707 (1994)CrossRefPubMed
82.
B.M. Arafah, S.H. Kailani, K.E. Nekl, R.S. Gold, W.R. Selman, Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J. Clin. Endocrinol. Metab. 79, 348–354 (1994)PubMed
83.
R. Comtois, H. Beauregard, M. Somma, O. Serri, N. Aris-Jilwan, J. Hardy, The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68, 860–866 (1991)CrossRefPubMed
84.
M.L. Cury, J.C. Fernandes, H.R. Machado, L.L. Elias, A.C. Moreira, M. Castro, Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq. Bras. Endocrinol. Metabol. 53, 31–39 (2009)CrossRefPubMed
85.
O.M. Dekkers, A.M. Pereira, J.A. Romijn, Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J. Clin. Endocrinol. Metab. 93, 3717–3726 (2008)CrossRefPubMed
86.
S. Cannavo, L. Curto, M. Venturino, S. Squadrito, B. Almoto, M.C. Narbone, R. Rao, F. Trimarchi, Abnormalities of hypothalamic-pituitary-thyroid axis in patients with primary empty sella. J. Endocrinol. Invest. 25, 236–239 (2002)CrossRefPubMed
87.
A. Giustina, G. Aimaretti, M. Bondanelli, F. Buzi, S. Cannavo, S. Cirillo, A. Colao, M.L. De, D. Ferone, M. Gasperi, S. Grottoli, T. Porcelli, E. Ghigo, U.E. degli, Primary empty sella: why and when to investigate hypothalamic-pituitary function. J. Endocrinol. Invest. 33, 343–346 (2010)CrossRefPubMed
88.
M.L. De, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty sella. J. Clin. Endocrinol. Metab. 90, 5471–5477 (2005)CrossRef
89.
M. Gasperi, G. Aimaretti, E. Cecconi, A. Colao, S.C. Di, S. Cannavo, C. Baffoni, M. Cosottini, L. Curto, F. Trimarchi, G. Lombardi, L. Grasso, E. Ghigo, E. Martino, Impairment of GH secretion in adults with primary empty sella. J. Endocrinol. Invest. 25, 329–333 (2002)CrossRefPubMed
90.
M. Klose, A. Juul, L. Poulsgaard, M. Kosteljanetz, J. Brennum, U. Feldt-Rasmussen, Prevalence and predictive factors of post-traumatic hypopituitarism. Clin. Endocrinol. 67, 193–201 (2007)CrossRef
91.
A. Agha, B. Rogers, M. Sherlock, P. O’Kelly, W. Tormey, J. Phillips, C.J. Thompson, Anterior pituitary dysfunction in survivors of traumatic brain injury. J. Clin. Endocrinol. Metab. 89, 4929–4936 (2004)CrossRefPubMed
92.
G. Aimaretti, M.R. Ambrosio, C. Di Somma, M. Gasperi, S.Cannavo, C. Scaroni, A. Fusco, P. Del Monte, E. De Menis, M. Faustini-Fustini, F. Grimaldi, F. Logoluso, P. Razzore, S. Rovere, S. Benvenga, E. C. Uberti, L. De Marinis, G. Lombardi, F. Mantero, E. Martino, G. Giordano, E. Ghigo: Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J. Clin. Endocrinol. Metab. (2005)
93.
C. Spielhagen, C. Schwahn, K. Moller, N. Friedrich, T. Kohlmann, J. Moock, M. Koltowska-Haggstrom, M. Nauck, M. Buchfelder, H. Wallaschofski, The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm. IGF Res. 21, 1–10 (2011)CrossRefPubMed
94.
K. Stochholm, C.H. Gravholt, T. Laursen, P. Laurberg, M. Andersen, L.O. Kristensen, U. Feldt-Rasmussen, J.S. Christiansen, M. Frydenberg, A. Green, Mortality and GH deficiency: a nationwide study. Eur. J. Endocrinol. 157, 9–18 (2007)CrossRefPubMed
95.
A. Agha, D. Walker, L. Perry, W.M. Drake, S.L. Chew, P.J. Jenkins, A.B. Grossman, J.P. Monson, Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin. Endocrinol. 66, 72–77 (2007)
96.
J.O. Jorgensen, H. Norrelund, N. Vahl, A. Juul, N.E. Skakkebaek, J.S. Christiansen, Continuation of growth hormone therapy versus placebo in transition-phase patients with growth hormone deficiency: impact on body composition, insulin sensitivity, and thyroid function. J. Pediatr. Endocrinol. Metab. 15(Suppl 5), 1355–1360 (2002)PubMed
97.
N. Kissell, J.O. Mudd, J.M. Gelow, L.E. Chong, K.C. Yuen, Cardiogenic shock due to non-ischemic cardiomyopathy induced by severe anterior hypopituitarism. AACC Clinical Case Reports. 1, e147-151 (2015)
Metadata
Title
Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients
Authors
Ulla Feldt-Rasmussen
Marianne Klose
Publication date
01-10-2016
Publisher
Springer US
Published in
Endocrine / Issue 1/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1047-x

Other articles of this Issue 1/2016

Endocrine 1/2016 Go to the issue

Original Article

Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience

Original Article

Serum anti-mullerian hormone and all-cause mortality in men

Original Article

The role of sex, adiposity, and gonadectomy in the regulation of irisin secretion

Original Article

Symptom-dependent cut-offs of urine metanephrines improve diagnostic accuracy for detecting pheochromocytomas in two separate cohorts, compared to symptom-independent cut-offs

Original Article

Insulin-sensitive adiposity is associated with a relatively lower risk of diabetes than insulin-resistant adiposity: the Bogalusa Heart Study

Endocrine Imaging

Benign hormone-secreting adenoma within a larger adrenocortical mass showing intensely increased activity on 18F-FDG PET/CT
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits